Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest Ranbaxy Laboratories Stories

2014-03-28 12:26:09

DUBLIN, March 28, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/lj5htc/investigation) has announced the addition of the "Investigation Report on China's Esomeprazole Market, 2009-2018" [http://www.researchandmarkets.com/research/lj5htc/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Digestive system disease is one of the most frequently occurring diseases....

2013-11-13 23:19:48

Reportbuyer.com just published a new market research report: PharmaSphere: Asia Pacific Deal Trends, 2004–2013. London (PRWEB) November 13, 2013 PharmaSphere: Asia Pacific Deal Trends, 2004–2013 Summary GlobalData’s report, "PharmaSphere: Asia Pacific Deal Trends, 2004–2013" offers an in-depth understanding of the key deals that took place in the region during the last decade. The type of deals covered in the report include Mergers & Acquisitions (M&A), Licensing...

2013-10-31 08:34:43

DUBLIN, Oct. 31, 2013 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Isotretinoin Capsules, 10 mg, 20 mg, 30 mg and 40 mg. Actavis' ANDA product is a generic version of Ranbaxy Inc.'s Absorica(®), which is a retinoid indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older. Cipher...

2013-10-03 23:21:24

Reportbuyer.com just published a new market research report: The World Generic Market Report 2013. London (PRWEB) October 03, 2013 A complete global analysis of the prospects for markets and companies in this dynamic industry sector Features and benefits of this thoroughly-researched and highly-regarded management report: High quality research and forecasts: Independent research, combined with detailed 5-year forecasts, informed commentary and unrivalled primary source data will aid your...

2013-09-24 23:03:56

Reportbuyer.com just published a new market research report: Pharma Leader Series: Top 50 Generic Drug Manufacturers 2013-2023. London (PRWEB) September 24, 2013 Report Details Generics companies - assess products, developments, and revenue prospects What does the future hold for makers of generic drugs? Visiongain's updated report shows you their prospects to 2023. There you see results, trends, opportunities, and revenue predictions. Our study analyses 50 leading generics producers...

2013-09-23 23:31:50

The Corporate Whistleblower Center is encouraging all pharmaceutical insiders with proof of company involvement in manufacturing or distributing adulterated drugs to contact them at 866-714-6466 for information about potential rewards. http://CorporateWhistleblowerCenter.Com (PRWEB) September 23, 2013 The Corporate Whistleblower Center says, "Rewards for whistleblowers in pharmaceutical companies can be staggering. According to a May 13th 2013 Department of Justice press release,...

2013-08-09 12:22:32

DUBLIN, August 9, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/92hzrx/global_api_market) have announced the addition of the "Global API Market Forecast to 2017" [http://www.researchandmarkets.com/research/92hzrx/global_api_market ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The market for Active Pharmaceutical Ingredients is brimming with activities. While it is consolidating...

2013-05-23 12:27:01

GURGAON, India, May 23, 2013 /PRNewswire/ -- On 22 May 2013, Daiichi Sankyo released a press statement where, among other things, it was stated that it "believes that certain former shareholders of Ranbaxy concealed and misrepresented critical information concerning the US DOJ and FDA investigations". The phrase is an obvious reference to the members and companies of the Singh family who were shareholders of Ranbaxy. Daiichi Sankyo's allegations of concealment and...

2013-05-22 08:29:45

TOKYO, May 22, 2013 /PRNewswire/ -- Ranbaxy Laboratories Limited (hereafter, Ranbaxy), a subsidiary of Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo), announced on May 22 the actions that Ranbaxy has taken in recent years to address past conduct under prior management (http://www.daiichisankyo.com/media_investors/media_relations/press_releases/index.html). Daiichi Sankyo continues to support Ranbaxy in its efforts to address and correct the conduct of the past which led to the...

2013-05-13 16:28:10

Stein Mitchell Muse & Cipollone LLP Announces Largest Generic Drug Whistleblower Settlement in History WASHINGTON, May 13, 2013 /PRNewswire-USNewswire/ -- Stein Mitchell Muse & Cipollone LLP announced today that Ranbaxy Laboratories Limited ("Ranbaxy"), India's largest generic drug manufacturer, has agreed to pay $500 million to the United States and individual States to resolve allegations by the law firm's client, Dinesh S. Thakur, that Ranbaxy falsified drug data and...